Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23951927 | 0.85 | DPP4 (0.46) | DPP4TP53MAPTLMNAPOLB | |
| SCHEMBL29661724 | 0.85 | DPP4 (0.46) | DPP4TP53MAPTLMNAPOLB | |
| SCHEMBL23067586 | 0.81 | CA12 (0.57) | DPP4MAPTPOLB | |
| SCHEMBL23387323 | 0.78 | CCNC (0.63) | CHRM4CHRM2 | |
| SCHEMBL23387271 | 0.78 | CCNC (0.63) | CHRM4CHRM2 | |
| SCHEMBL23387275 | 0.78 | CCNC (0.63) | CHRM4CHRM2 | |
| SCHEMBL21580294 | 0.77 | DPP4 (0.54) | DPP4CHRM4CHRM2 | |
| SCHEMBL30495509 | 0.77 | DPP4 (0.52) | DPP4CHRM4CHRM2 | |
| SCHEMBL23067588 | 0.77 | DPP4 (0.52) | DPP4CHRM4CHRM2 | |
| SCHEMBL23387260 | 0.76 | CCNC (0.56) | CHRM4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-20210323930-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | KINKI UNIVERSITY (JP) | 2021-10-21 | — | — | US | disclosed |
| EP-3572403-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2019-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | CACNA1I, CACNA1G, CACNA1H | DPP4 4341/4885TP53 3591/4885MAPT 176/4885 |
| US-20210323930-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | DPP4 4341/4885TP53 3591/4885MAPT 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.